<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1565">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05408780</url>
  </required_header>
  <id_info>
    <org_study_id>AC-22-028</org_study_id>
    <nct_id>NCT05408780</nct_id>
  </id_info>
  <brief_title>A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin, and Matching Placebo to Include Single-dose and Food Effect (Part A), and Titration Tolerability (Part B), in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerecin</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerecin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the PK, safety, and tolerability of a new liquid&#xD;
      formulation of tricaprilin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2022</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a two-part study.&#xD;
Part A (Food Effect Assessment): It is a randomized, double-blind (to IMP received), placebo-controlled, four-period, single-dose design. Subjects will be dosed in the fed state or the fasted state depending on the regimen.&#xD;
Part B (Titration Tolerability): Participants will be administered to either tricaprilin or a matching placebo.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) of total ketones (β-hydroxybutyrate and acetoacetate) after single-dose administration of tricaprilin and placebo formulations (Part A)</measure>
    <time_frame>0 to 8 hours post-dose</time_frame>
    <description>AUC will be calculated from PK concentrations of total ketones (B-hydroxybutyrate and Acetoacetate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (Part B)</measure>
    <time_frame>Baseline to 28 days</time_frame>
    <description>Adverse event incidence will be tabulated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (Part A)</measure>
    <time_frame>Baseline to 8 days</time_frame>
    <description>Adverse event incidence will be tabulated [BARF] Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of total ketones (β-hydroxybutyrate and acetoacetate) of tricaprilin and placebo formulations following a titration scheme (Part B)</measure>
    <time_frame>0 to 8 hours post-dose</time_frame>
    <description>AUC will be calculated from PK concentrations of total ketones (B-hydroxybutyrate and Acetoacetate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of total ketones (β-hydroxybutyrate and acetoacetate) after administration of tricaprilin and placebo formulations (Part A, Part B)</measure>
    <time_frame>0 to 8 hours post-dose</time_frame>
    <description>Cmax will be calculated from PK concentrations of total ketones (B-hydroxybutyrate and Acetoacetate)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Part A - Food Effect Assessment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized before administration of the first dose of active or matching placebo IMP in a 1:1:1:1 ratio to 1 of 4 treatment sequences (ABCD, BACD, ABDC, BADC) so that all subjects receive Regimens A, B, C and D across the 4 periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Titration Tolerability</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed BID in the morning and afternoon (approximately 5 h apart) on Days 1 to 27. Both doses of active or matching placebo IMP will be administered in the fed state either 30 min after completion of a standard-fat and calorie content breakfast or 30 min after a standardized-fat and calorie content lunch.&#xD;
Participants will be randomised to either study drug or the matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-OLE-01-VA</intervention_name>
    <description>formulation of tricaprilin or matching placebo</description>
    <arm_group_label>Part A - Food Effect Assessment</arm_group_label>
    <arm_group_label>Part B - Titration Tolerability</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and non-pregnant, non-lactating healthy females aged 18 to 55 years&#xD;
             inclusive at time of signing informed consent with a body weight ≥55 kg.&#xD;
&#xD;
          -  Body mass index (BMI) 18.0 to 32.0 kg/m2 as measured at screening or, if outside the&#xD;
             range, considered not clinically significant by the investigator.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Serious adverse reaction or serious hypersensitivity to any drug or formulation&#xD;
             excipients&#xD;
&#xD;
          -  Subjects with a history of fainting, dizziness, bradycardia or hypotension as&#xD;
             considered clinically significant by the investigator&#xD;
&#xD;
          -  Subject has a medical condition that may adversely affect taste or smell activity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Cerecin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>+65 6813 2999</phone>
    <email>clinical@cerecin.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Quotient Sciences Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suhaills Perez-Carrillo</last_name>
      <phone>305-644-9903</phone>
      <email>Suhaills.Perez-Carrillo@quotientsciences.com</email>
    </contact>
    <contact_backup>
      <last_name>IRB Advarra</last_name>
      <phone>+1 (410) 884-2900</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>May 31, 2022</study_first_submitted>
  <study_first_submitted_qc>June 5, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2022</study_first_posted>
  <last_update_submitted>July 18, 2022</last_update_submitted>
  <last_update_submitted_qc>July 18, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

